Document is current
Any future updates will be listed below
-
Authors
Hasenmajer, Valeria https://orcid.org/0000-0003-4301-6662
Ferrigno, Rosario https://orcid.org/0000-0002-8172-2405
Minnetti, Marianna https://orcid.org/0000-0002-9091-2809
Pellegrini, Bianca https://orcid.org/0000-0002-0496-8997
Isidori, Andrea M. https://orcid.org/0000-0002-9037-5417
Lenzi, Andrea https://orcid.org/0000-0002-7711-0465
Salerno, Mariacarolina https://orcid.org/0000-0003-1310-3300
Cappa, Marco https://orcid.org/0000-0001-5647-7519
Chan, Li https://orcid.org/0000-0001-5146-8242
De Martino, Maria Cristina https://orcid.org/0000-0003-3354-009X
Savage, Martin O. https://orcid.org/0000-0001-7902-3376
-
Funding
Funding for this research was provided by:
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2017HRTZYA, PRIN 2017N8CK4K)
- License Information
-
More Information
Article History
Accepted: 3 January 2023
First Online: 10 February 2023
Declarations
:
: VH, RF, MM, BP, AL, MCS, MC, MCDM, MOS have nothing to disclose. A.M.I. does consultancy for Novartis, Takeda, Recordati, and Sandoz companies and has received research grants and honoraria from Shire, IPSEN, and Pfizer company. LC does consultancy for OMass therapeutics.
: Not applicable.
: Not applicable.
: The authors have no conflicts of interest to report.
